The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive profits, the end of its exclusive rights opened the floodgates to cheaper https://bookmarkassist.com/story21524095/sildenafil-and-big-pharma-a-risky-opportunity